{"name":"Fisher & Paykel Healthcare","slug":"fisher-paykel","ticker":"FPH","exchange":"NZX","domain":"fphcare.com","description":"Fisher & Paykel Healthcare Corporation Limited (FPH) is a manufacturer, designer and marketer of products and systems for use in respiratory care, acute care, and the treatment of obstructive sleep apnea. Based in New Zealand, their products and systems are sold in around 120 countries worldwide. FPH is primarily an exporting company, with just 1 percent of revenue coming from New Zealand sales.","hq":"Auckland, New Zealand","founded":1934,"employees":"90","ceo":"Lewis Gradon","sector":"Medical Devices / Respiratory Care","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":4.92,"stockChange":0.09,"stockChangePercent":1.86,"marketCap":"$731M","metrics":{"revenue":110444000,"revenueGrowth":3.2,"grossMargin":45,"rdSpend":0,"netIncome":70966000,"cash":425546000,"dividendYield":0,"peRatio":8.1,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[{"date":"2024-02-22","type":"earnings","headline":"Fisher & Paykel Healthcare Reports Strong Half-Year Results","summary":"The company reported a 12% increase in revenue and a 15% increase in net profit for the half-year period.","drugName":"","sentiment":"positive"},{"date":"2023-11-15","type":"deal","headline":"Fisher & Paykel Healthcare Acquires US-Based Respiratory Care Company","summary":"The company acquired a US-based respiratory care company to expand its presence in the US market.","drugName":"","sentiment":"positive"},{"date":"2023-08-24","type":"regulatory","headline":"Fisher & Paykel Healthcare Receives FDA Clearance for New Respiratory Care Product","summary":"The company received FDA clearance for a new respiratory care product, expanding its product portfolio.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-06","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiekFVX3lxTE5zM3VoSV9qQ0RoM2d3R1duUW5zcmt6aTl1RXFVUXcteldYLWo3Zl93UmZkbW9FamZaQkxRdU9kTVYwbnJHWTNERWN5SS15VVhmOUdOdHhZRHFFZHJsa2djZHdGR21OSGpEazBZNXdvWG1xODZjTkpyaERR?oc=5","date":"2026-02-24","type":"deal","source":"Stocks Down Under","summary":"Is Fisher & Paykel Healthcare (ASX:FPH) a Buy After Upgrading Guidance? The Tariff Risk Investors Are Ignoring - Stocks Down Under","headline":"Is Fisher & Paykel Healthcare (ASX:FPH) a Buy After Upgrading Guidance? The Tariff Risk Investors Are Ignoring","sentiment":"neutral"},{"date":"2026-02-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-01-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxOc0M4d0tucDQyV051aWZmRVVUZ18zaWphdHc5NXBFOXg1LW1mOWgxLWw3Z2syWGFUbzZnTTZEWnNBMGw0V0RVV2gzc3VVcEt0M0N5NVlFRVRYN2RYWmRLbHVYcUVQdjBLNHg1NXl1X19XR3c1TEh2X3V4ejF4elFCTFBvNFdsUQ?oc=5","date":"2026-01-13","type":"pipeline","source":"HME Business","summary":"Fisher & Paykel’s F&P Nova Nasal Mask Now Available in US - HME Business","headline":"Fisher & Paykel’s F&P Nova Nasal Mask Now Available in US","sentiment":"neutral"},{"date":"2025-10-31","type":"earnings","source":"SEC EDGAR","summary":"10-Q filed with SEC: 10-Q","headline":"Quarterly Report (10-Q) Filed","sentiment":"neutral"},{"date":"2025-10-29","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-10-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxNU2JJVC1xTTVieTNoSjl1TXYwYzVJTUhySWJsTXBaLXFSTkdvaGxFdWVsMm9mc3BMS2tqVlY2enZsLVNUMl9hR3ViaTRpZlJYSFFTQVVZbkVSbThxbkFQMjdndzhjN25IQndzRGlwaDZuRzJiUjE2NXdiWnhiY1NhQmhHTm1XbHZiMU5heU82V0UwVVg3eERLXzNVZml5ZF9pOGZ5VTJMRkVmcHVncm5IcFJRVjdXSmtGRlVhZXVVWllDNFJkV0Vn?oc=5","date":"2025-10-01","type":"pipeline","source":"BusinessDesk | NZ","summary":"Trump tariff 'panic': Drug maker Douglas Pharmaceuticals urges incentives not punishment - BusinessDesk | NZ","headline":"Trump tariff 'panic': Drug maker Douglas Pharmaceuticals urges incentives not punishment - BusinessDesk | NZ","sentiment":"neutral"},{"date":"2025-09-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2025-09-22","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOc2ltZEhMNVZ3UXN3MUdlVjBvbzZSRml5NlV1VGJ5MEZNNk1ITFAtSDF1RThoWFJ5ZUo3c1N6ZWdNeTN6am1oYXpfVXB3bWFMa3gxZ1VtN2hYNHBkYmhQVFEwZFBuNV8yUnhJdnpLZnotVVFoQ0lEaUJXdXNVQTIzTHlTSTk0VVZRU1lFTTJrU0JuZHVtNU5zeGxDZFF0V3k3RF9oN0E1MGVSb1FoS0ZlakFYZzFLek5K?oc=5","date":"2025-08-04","type":"pipeline","source":"The Motley Fool Australia","summary":"CSL, Telix and more: Key reporting dates for 10 ASX 200 healthcare stocks in August - The Motley Fool Australia","headline":"CSL, Telix and more: Key reporting dates for 10 ASX 200 healthcare stocks in August","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxNY21kazJ5cGlXaXpTYWdPX1RLbXcyRmxLcG4wRXc3Ry1tbHhBTVJIcW1JMlBYUHltSVppaWNTSFlFWmd6czJGeUVxLXF3QlJ0RXhRdmEwOFhIRHlWNmlzMFQ1LW1yNWJKc1pDVC10djduRXU2allqa1NJQTZiWDZoR1pqODNKcTRVLURDSXRRenVZbDExa3c?oc=5","date":"2025-06-03","type":"deal","source":"The Motley Fool Australia","summary":"Why does Macquarie think Fisher & Paykel shares are a buy? - The Motley Fool Australia","headline":"Why does Macquarie think Fisher & Paykel shares are a buy?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxPQm81aEM0LUN3Wk9pZFQ4TnVQbXBwWmNOVTBNSnRSemdlVnFsVUt3dlVoQ0t2U2lib3lOM1prTTRkVGxMTFMydzhBVGgzaVVXMEFoaHc0ZGtxX1BSU1diaEN0NkV2RXJkdkNDV29Ub1J6US12TmJ1ZC1ocGxad1ZIZGdyNGhkdkVGRDFDNEdLb0xGNXAzbFJlRGZqSGJFUVJlenZGaU02NzMxQ01qQ3czOTF6Qm9jZw?oc=5","date":"2025-05-30","type":"earnings","source":"HME Business","summary":"Fisher & Paykel Breaks $2 Billion Revenue Mark with Growth in OSA Masks, Hospital Consumables - HME Business","headline":"Fisher & Paykel Breaks $2 Billion Revenue Mark with Growth in OSA Masks, Hospital Consumables","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNMkpKblBZbDZBZ2NpaG1oeEpuLXk4N0pPOHl6YnExeXhSQ2JZcVBieWFkV2dBVDBwaUpZU3lqVmhqRC1aQVFwcEh1ZnVTaVhYbDZvcTYydTlEblFVbEFsanh1N191bTI2NVFybHg0S1N6VVZEMmJXa1ZFbHk3MzlYRVBZLXFEZDNmeEEyUmNTRjl2VGpLUW5xQS1jbDlDUURvd1E?oc=5","date":"2025-04-15","type":"pipeline","source":"Market Index","summary":"How do CSL, ResMed, Cochlear and Ansell fare against Trump tariffs? - Market Index","headline":"How do CSL, ResMed, Cochlear and Ansell fare against Trump tariffs?","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":2,"keyCompetitors":["ResMed","Philips Healthcare","Masimo"],"therapeuticFocus":["Respiratory Care"],"financials":{"source":"sec_edgar+yahoo","revenue":110020000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":110020000,"period":"2025-12-31"},{"value":237926000,"period":"2024-12-31"},{"value":211732000,"period":"2023-12-31"},{"value":42694000,"period":"2022-12-31"},{"value":224394000,"period":"2021-12-31"},{"value":153619000,"period":"2020-12-31"}],"grossProfit":53229000,"grossProfitHistory":[{"period":"2025-12-31","value":53229000},{"period":"2024-12-31","value":118831000},{"period":"2023-12-31","value":77744000},{"period":"2022-12-31","value":15199000}],"rdSpend":null,"rdSpendHistory":[],"sgaSpend":60617000,"operatingIncome":-7388000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-7388000},{"period":"2024-12-31","value":67598000},{"period":"2023-12-31","value":26249000},{"period":"2022-12-31","value":-39392000}],"netIncome":70966000,"netIncomeHistory":[{"period":"2025-12-31","value":70966000},{"period":"2024-12-31","value":68297000},{"period":"2023-12-31","value":55394000},{"period":"2022-12-31","value":-15403000}],"eps":0.96,"epsHistory":[{"period":"2025-12-31","value":0.96},{"period":"2024-12-31","value":0.96},{"period":"2023-12-31","value":0.76},{"period":"2022-12-31","value":-0.23}],"cash":425546000,"cashHistory":[{"period":"2025-12-31","value":425546000},{"period":"2024-12-31","value":430875000},{"period":"2023-12-31","value":353801000},{"period":"2022-12-31","value":131771000}],"totalAssets":3249003000,"totalLiabilities":860407000,"totalDebt":443348000,"equity":843245000,"operatingCashflow":105230000,"operatingCashflowHistory":[{"period":"2025-12-31","value":105230000},{"period":"2024-12-31","value":115986000},{"period":"2023-12-31","value":154123000},{"period":"2022-12-31","value":-188302000}],"capex":null,"capexHistory":[],"freeCashflow":105230000,"dividendsPaid":0,"buybacks":null,"employees":90,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":14749000,"ebit":-9642000,"ebitda":-7916000,"period":"2026-03-31","revenue":13581000,"epsBasic":-0.03,"netIncome":-2227000,"rdExpense":null,"epsDiluted":-0.03,"grossProfit":5107000,"operatingIncome":-9642000},{"sga":15972000,"ebit":18876000,"ebitda":22370000,"period":"2025-12-31","revenue":75902000,"epsBasic":0.33,"netIncome":23291000,"rdExpense":null,"epsDiluted":0.31,"grossProfit":34848000,"operatingIncome":18876000},{"sga":14294000,"ebit":-7892000,"ebitda":-5906000,"period":"2025-09-30","revenue":13488000,"epsBasic":0.3,"netIncome":21071000,"rdExpense":null,"epsDiluted":0.28,"grossProfit":6402000,"operatingIncome":-7892000},{"sga":15586000,"ebit":-12216000,"ebitda":-10955000,"period":"2025-06-30","revenue":7473000,"epsBasic":0.05,"netIncome":3320000,"rdExpense":null,"epsDiluted":0.05,"grossProfit":3370000,"operatingIncome":-12216000},{"sga":14765000,"ebit":-6156000,"ebitda":-4142000,"period":"2025-03-31","revenue":13157000,"epsBasic":0.33,"netIncome":23284000,"rdExpense":null,"epsDiluted":0.32,"grossProfit":8609000,"operatingIncome":-6156000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-12-31","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.92,"previousClose":4.83,"fiftyTwoWeekHigh":6.64,"fiftyTwoWeekLow":4.72,"fiftyTwoWeekRange":"4.72 - 6.64","fiftyDayAverage":5.02,"twoHundredDayAverage":5.57,"beta":1.35,"enterpriseValue":2024223616,"forwardPE":7.5,"priceToBook":0.42,"priceToSales":6.62,"enterpriseToRevenue":18.33,"enterpriseToEbitda":-870.26,"pegRatio":0,"ebitda":-2326000,"ebitdaMargin":-2.1,"freeCashflow":-125328624,"operatingCashflow":3999000,"totalDebt":471582016,"debtToEquity":19.8,"currentRatio":66.35,"returnOnAssets":-0.2,"returnOnEquity":5.1,"analystRating":"","recommendationKey":"none","numberOfAnalysts":0,"targetMeanPrice":0,"targetHighPrice":0,"targetLowPrice":0,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":16.3,"institutionHeldPercent":57.1,"sharesOutstanding":72406686,"floatShares":63702483,"sharesShort":428728,"shortRatio":2.43,"shortPercentOfFloat":0.6,"epsTrailing":0.61,"epsForward":0.66,"revenuePerShare":1.57,"bookValue":11.86,"officers":[{"age":67,"name":"Mr. Stuart A. Miller","title":"Executive Chairman"},{"age":71,"name":"Mr. Daniel C. Hedigan J.D.","title":"President & CEO"},{"age":66,"name":"Mr. Emile K. Haddad","title":"Founder & Chairman Emeritus"},{"age":65,"name":"Mr. Kim  Tobler","title":"CFO, VP & Treasurer"},{"age":59,"name":"Mr. Michael A. Alvarado J.D.","title":"COO, Chief Legal Officer & VP"},{"age":73,"name":"Mr. Greg  McWilliams","title":"Chief Policy Officer & VP"},{"age":60,"name":"Mr. Leo  Kij","title":"Senior Vice President of Financial Reporting"}],"industry":"Real Estate - Development","irWebsite":"","website":"https://www.fivepoint.com","phone":"949 349 1000"}}